Company: THC
Filing Date: 2025-04-29
Form Type: 10-Q
Source: 0000070318-25-000017
Chunk: 100

Company: TENET HEALTHCARE CORP
Filing Date: 2025-04-29
Form: 10-Q
Item: Part I, Item 8
Chunk 100
---
forwards primarily due to gains from sales of facilities.There were no adjustments to our estimated liabilities for uncertain tax positions during the three months ended March 31, 2025. The total amount of unrecognized tax benefits as of March 31, 2025 was $71 million, of which $69 million, if recognized, would affect our effective tax rate and income tax benefit.Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our condensed consolidated statements of operations. Approximately $1 million of interest and penalties related to accrued liabilities for uncertain tax positions are included for the three months ended March 31, 2025. Total accrued interest and penalties on unrecognized tax benefits at March 31, 2025 were $9 million.

NOTE 14. EARNINGS PER COMMON SHARE

The following table reconciles the numerators and denominators of our basic and diluted earnings per common share calculations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands. Net Income Available to CommonShareholders(Numerator)Weighted Average Shares(Denominator)Per-Share AmountThree Months Ended March 31, 2025   Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$406 94,242 $4.31 Effect of dilutive instruments— 777 (0.04)Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$406 95,019 $4.27 Three Months Ended March 31, 2024   Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$2,151 99,581 $21.60 Effect of dilutive instruments— 1,017 (0.22)Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$2,151 100,598 $21.38 

15

Dilutive instruments during the three months ended March 31, 2025 and 2024 consisted of stock options, RSUs, deferred compensation units and dividends on subsidiary preferred stock. During the three-month period in 2024, our dilutive instruments also included RSUs issued under USPI’s restricted stock plan.

NOTE 15. FAIR VALUE MEASUREMENTS 

We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value.